Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases

被引:10
作者
Anyfanti, Panagiota [1 ]
Dara, Athanasia [2 ]
Angeloudi, Elena [1 ]
Bekiari, Eleni [1 ]
Dimitroulas, Theodoros [2 ]
Kitas, George D. [3 ,4 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Med Dept 2, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Internal Med 4, Thessaloniki, Greece
[3] Russells Hall Hosp, Dept Rheumatol, Dudley Grp NHS Fdn Trust, Dudley, England
[4] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England
关键词
chronic inflammatory diseases; cardiovascular risk assessment; lifestyle modifications; pharmacological management; SYSTEMIC-LUPUS-ERYTHEMATOSUS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; SUBCLINICAL ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION; PSORIATIC-ARTHRITIS; ANTIRHEUMATIC DRUGS; ALPHA THERAPY; METHOTREXATE; VALIDATION;
D O I
10.2147/JIR.S276986
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cardiovascular disease (CVD) is common in immune-mediated inflammatory diseases (IMIDs) and it is predominately attributed to the interplay between chronic inflammation and traditional CVD risk factors. CVD has significant impact on the survival of patients with IMIDs as it is associated with increased morbidity and mortality. Despite recommendations for monitoring and managing CVD in patients with IMIDs, the individual CVD risk assessment remains problematic as CVD risk calculators for the general population consistently underestimate the risk in patients with IMIDs. Application of new technologies utilizing artificial intelligence techniques have shown promising potential for tailoring predictive medicine to the individual patient, but further validation of their role in clinical decision-making is warranted. In the meantime, individuals with IMIDs should be encouraged to adopt behavioral interventions targeting at modifiable lifestyle CVD risk factors, whereas rheumatologists need to be well aware of the unfavorable effects of antirheumatic medication on various CVD risk factors and outcomes. In the current paper, we aim to provide an overview of current and emerging strategies for mitigating CVD risk in patients with IMIDs, based on a practical approach.
引用
收藏
页码:6893 / 6906
页数:14
相关论文
共 128 条
  • [1] EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
    Agca, R.
    Heslinga, S. C.
    Rollefstad, S.
    Heslinga, M.
    McInnes, B.
    Peters, M. J. L.
    Kvien, T. K.
    Dougados, M.
    Radner, H.
    Atzeni, F.
    Primdahl, J.
    Sodergren, A.
    Jonsson, S. Wallberg
    van Rompay, J.
    Zabalan, C.
    Pedersen, T. R.
    Jacobsson, L.
    de Vlam, K.
    Gonzalez-Gay, M. A.
    Semb, A. G.
    Kitas, G. D.
    Smulders, Y. M.
    Szekanecz, Z.
    Sattar, N.
    Symmons, D. P. M.
    Nurmohamed, M. T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 17 - 28
  • [2] Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis
    Alemao, Evo
    Cawston, Helene
    Bourhis, Francois
    Al, Maiwenn
    Rutten-van Molken, Maureen
    Liao, Katherine P.
    Solomon, Daniel H.
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 777 - 786
  • [3] [Anonymous], 2016, MEDITERR J RHEUMATOL, DOI DOI 10.31138/MJR.27.2.48
  • [4] Endothelial Dysfunction in Patients with Rheumatoid Arthritis: the Role of Hypertension
    Anyfanti, P.
    Gavriilaki, E.
    Douma, S.
    Gkaliagkousi, E.
    [J]. CURRENT HYPERTENSION REPORTS, 2020, 22 (08)
  • [5] Depression, anxiety, and quality of life in a large cohort of patients with rheumatic diseases: common, yet undertreated
    Anyfanti, Panagiota
    Gavriilaki, Eleni
    Pyrpasopoulou, Athina
    Triantafyllou, George
    Triantafyllou, Areti
    Chatzimichailidou, Sofia
    Gkaliagkousi, Eugenia
    Aslanidis, Spyros
    Douma, Stella
    [J]. CLINICAL RHEUMATOLOGY, 2016, 35 (03) : 733 - 739
  • [6] Association of galectin-3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis
    Anyfanti, Panagiota
    Gkaliagkousi, Eugenia
    Gavriilaki, Eleni
    Triantafyllou, Areti
    Dolgyras, Panagiotis
    Galanopoulou, Vasiliki
    Aslanidis, Spyros
    Douma, Stella
    [J]. CLINICAL CARDIOLOGY, 2019, 42 (01) : 62 - 68
  • [7] Dermal capillary rarefaction as a marker of microvascular damage in patients with rheumatoid arthritis: Association with inflammation and disorders of the macrocirculation
    Anyfanti, Panagiota
    Gkaliagkousi, Eugenia
    Triantafyllou, Areti
    Zabulis, Xenophon
    Dolgyras, Panagiotis
    Galanopoulou, Vasiliki
    Aslanidis, Spyros
    Douma, Stella
    [J]. MICROCIRCULATION, 2018, 25 (05)
  • [8] Retinal vessel morphology in rheumatoid arthritis: Association with systemic inflammation, subclinical atherosclerosis, and cardiovascular risk
    Anyfanti, Panagiota
    Triantafyllou, Areti
    Gkaliagkousi, Eugenia
    Koletsos, Nikolaos
    Athanasopoulos, Georgios
    Zabulis, Xenophon
    Galanopoulou, Vasiliki
    Aslanidis, Spyros
    Douma, Stella
    [J]. MICROCIRCULATION, 2017, 24 (08)
  • [9] Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors
    Anyfanti, Panagiota
    Triantafyllou, Areti
    Gkaliagkousi, Eugenia
    Triantafyllou, Georgios
    Koletsos, Nikolaos
    Chatzimichailidou, Sophia
    Panagopoulos, Panagiotis
    Botis, Ioannis
    Aslanidis, Spyros
    Douma, Stella
    [J]. CLINICAL RHEUMATOLOGY, 2017, 36 (06) : 1229 - 1236
  • [10] Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases
    Arida, Aikaterini
    Protogerou, Athanasios D.
    Kitas, George D.
    Sfikakis, Petros P.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (07)